Blood Neoplasia
Издатель: Elsevier · ISSN 2950-3280 · 100 статей
- Somatic UBA1 mutations in pediatric MDS/AML: first cases suggest distinct pathogenesis from adult VEXAS syndrome
- Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera
- Evaluating response criteria in myelodysplastic/myeloproliferative neoplasms: a systematic review and meta-analysis
- FLT3 (CD135) expression in pediatric AML is associated with distinct features and worse outcomes with sorafenib therapy
- Multilayer modeling reveals an endogenous retrovirus signature predictive of induction chemotherapy failure in AML
- Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.
- EZH2-driven immune evasion at disease presentation defines high-risk t(16;21) FUS::ERG pediatric AML
- Long-read cDNA sequencing reveals novel isoforms and spliceosome mutant-enriched transcripts in AML and MDS cells
- Dasatinib-based induction and blinatumomab + TKI consolidation/maintenance for BCR::ABL1+ ALL: BLISSPhALL Study Results
- Trends in Survival of Marginal Zone Lymphoma by Treatment Era in the United States
- AML/MDS patients with DDX41 (DEAD-box helicase 41) germline variants: A single-center experience
- Prospective Analyses of the Utility of Liquid Biopsy in Patients with Fever of Unknown Origin Suspected of Lymphoma
- Prognostic and Serial Assessment of Functional/Psychosocial Factors in Older Adults Receiving AML Induction Chemotherapy
- Disrupting RNA Splicing Sensitizes T-ALL Cells to Proteasome Blockade
- Out-of-frame but not out-of-function: cryptic mRNA splicing in FLT3 internal tandem duplications
- Resistance to CD20×CD3 Bispecific Antibodies in B-Cell Lymphoma: Mechanisms and Emerging Therapeutic Strategies
- Unmasking BCL2A1: IL10/STAT3-Driven BCL2A1 Expression Promotes Apoptosis Resistance in DLBCL
- Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma
- Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia
- Targeted Therapy Yields Early Neurologic Improvement in Central Nervous System Histiocytic Neoplasms
- Safety Outcomes of First-Line Venetoclax vs Second-Generation BTKi in CLL/SLL: A Retrospective Cohort Study
- Lineage switch in leukemia and lymphoma: case reports and molecular and cellular mechanisms
- Exercise and nutrition in hematologic malignancies: translational evidence and emerging interventions
- Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients
- Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study
- Deuterium labeling uncovers deregulated myeloid cell kinetics in chronic myelomonocytic leukemia
- Favezelimab plus pembrolizumab for anti–PD-1–refractory classic Hodgkin lymphoma: an open-label phase 1/2 study
- Treatment preferences in Waldenström macroglobulinemia: an international discrete choice experiment in 1455 patients
- Targeting ROR1 with KAN571C disrupts resistance networks in mantle cell lymphoma
- Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis